ITCI

Intra-Cellular Therapies Inc.

Price

return (12m)

p/e

-187.17

p/bv

12.17

DIVIDEND YIELD

0.00%

ITCI price

Intra-Cellular Therapies

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ITCI

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals ITCI

Valuation

P/E

-187.17

Sector 1.09

Industry -1.78

P/BV

12.17

Sector 1.86

Industry 1.35

P/Revenue (PSR)

20.54

Sector 1.55

Industry 2.25

EV/EBITDA

-446.10

Sector -47.62

Industry -42.38

EV/EBIT

-444.42

Sector -27.52

Industry -45.58

P/EBITDA

-120.28

Sector -32.64

Industry -23.10

P/EBIT

-119.76

Sector -43.02

Industry -27.18

P/Total Assets

10.23

Sector 0.87

Industry 0.82

P/Net Current Assets

12.84

Sector -27.09

Industry -72.46

P/Working Capital

12.69

Sector -4.05

Industry -2.10

EPS

-0.70

Sector -0.70

Industry -1.11

BVPS

10.83

Sector 4.34

Industry 2.54

Efficiency

Gross Margin

91.63%

Sector 49.36%

Industry 50.48%

EBITDA Margin

-14.60%

Sector -283.40%

Industry -17,123,193.33%

EBIT Margin

-14.66%

Sector -164.84%

Industry -17,075,660.18%

Operating Margin

-17.15%

Sector -19.73%

Industry -25.75%

Net Profit Margins

-10.97%

Sector -24.22%

Industry -27.82%

Asset Turnover

0.15

Sector 0.13

Industry 0.06

Profitability

ROE

-6.50%

Sector -24.32%

Industry -33.33%

ROA

-5.46%

Sector -24.41%

Industry -45.72%

ROIC

-59.61%

Sector -529.97%

Industry -855.00%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

6.36

Sector 1.90

Industry 2.51

Net Debt / EBITDA

34.41

Sector -4.96

Industry -8.98

Net Debt / EBIT

34.28

Sector -3.08

Industry -37.38

Net Debt / Equity

-0.87

Sector -0.45

Industry -1.16

Gross Debt / Equity

0.00

Sector -0.74

Industry -0.56

Equity/Assets

0.84

Sector 0.46

Industry 0.52

Liabilities/Assets

0.16

Sector 0.49

Industry 0.47

Growth

5Y Revenue CAGR

51.81%

Sector -

Industry -

5Y Earnings CAGR

-23.45%

Sector -

Industry -

Fundamentals ITCI

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ITCI Intra-Cellular Therapies Inc.	$0.00	-	0.00%	-187.17	12.17	-6.50%	-10.97%
LLY Eli Lilly and Compay	$1,142.35	51.23%	0.59%	38.16	30.09	78.84%	33.53%
SNY Sanofi	$42.38	-6.23%	4.17%	3.97	0.73	18.43%	14.25%
GSK GlaxoSmithKline PLC	$50.03	29.66%	3.54%	15.39	4.35	28.24%	14.54%
CRMD CorMedix Inc.	$7.69	-30.85%	0.00%	3.22	1.31	40.62%	40.49%
AMPH Amphastar Pharmaceuticals Inc.	$23.73	-12.06%	0.00%	13.18	1.35	10.23%	10.76%
RDY Dr. Reddy's Laboratories Ltd.	$12.16	-17.58%	0.69%	27.59	2.49	9.03%	10.14%
ENLV Enlivex Therapeutics Ltd.	$0.78	-95.06%	0.00%	0.01	0.01	63.85%	0.00%
ISRG Intuitive Surgical Inc.	$392.49	-9.49%	0.00%	44.01	7.60	17.26%	28.62%
NVS Novartis AG	$139.78	16.35%	2.22%	20.89	6.35	30.39%	23.28%
TMO Thermo Fisher Scientific Inc.	$653.75	38.92%	0.28%	34.71	4.60	13.25%	15.07%
ABT Abbott Laboratories	$102.63	-21.99%	2.25%	35.46	3.76	10.61%	11.65%
MDT Medtronic PLC	$92.33	1.59%	3.11%	22.28	2.31	10.35%	14.02%
BSX Boston Scientific Corp.	$43.52	-55.82%	0.00%	17.60	2.59	14.73%	17.49%
TMDX TransMedics Group Inc.	$87.47	-27.00%	0.00%	19.94	5.84	29.28%	22.69%
RMD ResMed Inc.	$227.07	-15.55%	0.80%	21.51	4.98	23.13%	26.94%
IDXX IDEXX Laboratories Inc.	$512.11	-20.09%	0.00%	35.48	25.07	70.67%	25.03%
HCA HCA Healthcare Inc.	$429.56	8.26%	0.70%	12.06	-29.52	-244.72%	10.07%
COHR Coherent Inc.	$308.78	198.60%	0.00%	75.62	5.36	7.09%	11.19%
DHR Danaher Corporation	$211.66	9.40%	0.68%	37.21	2.83	7.61%	15.95%
SYK Stryker Corp.	$276.81	-25.56%	1.26%	28.38	4.41	15.55%	14.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ITCI Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Intra-Cellular Therapies

Intra-Cellular Therapies Inc.

Average Investor10 user rating

4.0 (0 people)

United States

14 years

Founded: 2012

2013

Time since IPO - 13 years

512

Employees

Intra-Cellular Therapies Inc. (United States) is listed on the Nasdaq and has a market capitalization of $13.98 billion, with shareholders equity totaling $1.15 billion.

The company employs approximately 512 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Intra-Cellular Therapies Inc. reported $680.50 million in revenue, generating net income of $-74.68 million.

Key financial metrics include a P/E ratio of -187.17, a price-to-book (P/B) ratio of 12.17, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ITCI.

Market cap

$13.98 billion

Net worth

$1.15 billion

$1,148,460,000.00

Assets

$1.37 billion

$1,366,910,000.00

Total Shares Outstanding

106.00 million

106,000,000

Average Daily Trading Volume

$2.26 million

$2,259,894.86

Sector

Health

Industry

Pharmaceutical Products

ITCI

ITCI revenue and profits

Financial Results ITCI

DRAG THE FRAME TO SEE MORE DATA

ITCI cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$88.45 21,79% (12M)

P/E

-0.79

3.01%

ROE

-178.93%

P/BV

1.42

CI - Cigna

$275.31 --3,58% (12M)

P/E

10.57

1.69%

ROE

16.04%

P/BV

1.70

CNC - Centene

$65.99 107,71% (12M)

P/E

-6.38

0.00%

ROE

-22.56%

P/BV

1.44

HUM - Humana

$384.07 54,21% (12M)

P/E

35.53

0.93%

ROE

6.72%

P/BV

2.39

SNY - Sanofi

$42.38 --7,54% (12M)

P/E

3.97

4.17%

ROE

18.43%

P/BV

0.73

LLY - Eli Lilly

$1,142.35 52,87% (12M)

P/E

38.16

0.59%

ROE

78.84%

P/BV

30.09

HCA - HCA Healthcare

$429.56 7,48% (12M)

P/E

12.06

0.70%

ROE

-244.72%

P/BV

-29.52

NVS - Novartis

$139.78 15,92% (12M)

P/E

20.89

2.22%

ROE

30.39%

P/BV

6.35